- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit ...

PTC Therapeutics has agreed to a licensing deal with Swiss pharmaceutical firm Roche for its spinal muscular atrophy program that could be worth as much as $490 million. Under the terms of the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

(RTTNews) - Biopharmaceutical company PTC Therapeutics, Inc. (PTCT) announced Monday the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corp., a ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Novartis is paying $1 billion upfront in a licensing deal for an ...

Novartis will pay PTC Therapeutics up to $2.9 billion for its oral therapy to treat Huntington’s disease in a deal announced Monday morning. As part of the agreement, PTC Therapeutics will receive $1 ...

PTC to get $12 million upfront with a potential to earn $200 million if certain milestones are reached.Kenilworth-based Schering-Plough (NYSE: SGP) has entered into an exclusive collaboration and ...

PTC Therapeutics signed a $1billion upfront deal with Novartis for its Huntington's program, with potential milestones of $1.9 billion. Interim Phase 2 data shows PTC518 reduces mutant protein levels ...

On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE:NVS) for its PTC518 Huntington’s disease program, which includes ...